MA27442A1 - Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf) - Google Patents
Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)Info
- Publication number
- MA27442A1 MA27442A1 MA28156A MA28156A MA27442A1 MA 27442 A1 MA27442 A1 MA 27442A1 MA 28156 A MA28156 A MA 28156A MA 28156 A MA28156 A MA 28156A MA 27442 A1 MA27442 A1 MA 27442A1
- Authority
- MA
- Morocco
- Prior art keywords
- tgf
- growth factor
- transforming growth
- triazole derivatives
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 18 Septembre 2002 60/412,079 US 2 Juillet 2003 60/484,535 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de triazole servant d'inhibiteurs du facteur de croissance transformant Des dérivés de triazole nouveaux de formule (Ia-c), des intermédiaires pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en médecine sont décrits. Les composés de la présente invention sont de puissants inhibiteurs de la voie de transmission de signal du facteur de croissance transformant ("TGF")-(bêta). Ils sont utiles dans le traitement de divers états pathologiques en rapport avec le TGF comprenant, par exemple, le cancer et des maladies fibrotiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41207902P | 2002-09-18 | 2002-09-18 | |
US48453503P | 2003-07-02 | 2003-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27442A1 true MA27442A1 (fr) | 2005-07-01 |
Family
ID=32033582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28156A MA27442A1 (fr) | 2002-09-18 | 2005-03-18 | Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf) |
Country Status (25)
Country | Link |
---|---|
US (2) | US7053095B2 (fr) |
EP (1) | EP1542685A1 (fr) |
JP (1) | JP2006502236A (fr) |
KR (1) | KR20050057393A (fr) |
CN (1) | CN1681502A (fr) |
AP (1) | AP2005003260A0 (fr) |
AR (1) | AR041276A1 (fr) |
AU (1) | AU2003260810A1 (fr) |
BR (1) | BR0314577A (fr) |
CA (1) | CA2497971A1 (fr) |
CO (1) | CO5540390A2 (fr) |
EA (1) | EA200500376A1 (fr) |
EC (1) | ECSP055681A (fr) |
HR (1) | HRP20050251A2 (fr) |
IS (1) | IS7713A (fr) |
MA (1) | MA27442A1 (fr) |
MX (1) | MXPA05002982A (fr) |
NO (1) | NO20051010L (fr) |
OA (1) | OA12927A (fr) |
PA (1) | PA8583401A1 (fr) |
PE (1) | PE20050074A1 (fr) |
PL (1) | PL375974A1 (fr) |
TW (1) | TW200412346A (fr) |
UY (1) | UY27981A1 (fr) |
WO (1) | WO2004026307A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
BR0314383A (pt) | 2002-09-18 | 2005-07-19 | Pfizer Prod Inc | Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) |
OA12928A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGF) inhibitors. |
WO2004026306A2 (fr) * | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Nouveaux composes de pyrazole utilises comme inhibiteurs du facteur de croissance transformant (tgf) |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
PT1854789E (pt) | 2005-02-23 | 2013-10-23 | Shionogi & Co | Derivado de quinazolina possuindo actividade inibidora de tirosina-cinase |
EP1919881B1 (fr) * | 2005-07-25 | 2013-04-10 | Synta Pharmaceuticals Corp. | 1,2,3-inhibiteurs de la polymererization de la tubuline pour le traitement de maladies proliferatives |
WO2007070866A2 (fr) * | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Controle de la pression intraoculaire a l'aide d'agents de modulation d'alk5 |
DE102005061840A1 (de) | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
WO2008009077A2 (fr) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Dérivés quinazoline 4,6-disubstitués et 2,4,6-trisubstitués et compositions pharmaceutiques utiles pour traiter des infections virales |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
US10023640B2 (en) | 2012-10-05 | 2018-07-17 | Kadmon Corporation, Llc | Human anti-VEGFR-2/KDR antibodies |
DK2970890T3 (da) | 2013-03-14 | 2020-05-04 | Brigham & Womens Hospital Inc | Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller |
ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
WO2016037016A1 (fr) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systèmes et procédés pour la production de cellules ciliées de l'oreille interne pour le traitement de la perte auditive |
EA035093B1 (ru) | 2015-03-04 | 2020-04-27 | Джилид Сайэнс, Инк. | 4,6-диаминопиридо[3,2-d]пиримидиновые соединения, модулирующие toll-подобные рецепторы |
US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
WO2018045150A1 (fr) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll |
AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
CA3093340A1 (fr) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Composes inhibiteurs de kinase, compositions et procedes d'utilisation |
WO2020019108A1 (fr) | 2018-07-23 | 2020-01-30 | Guangzhou Othrotx Co., Ltd. | Conjugués médicamenteux à base de bisphosphonate |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
EP3837352A1 (fr) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions et méthodes pour générer des cellules ciliées par la régulation à la hausse de jag-1 |
AU2019419414A1 (en) | 2018-12-31 | 2023-04-06 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
CN112694477B (zh) * | 2019-10-22 | 2024-02-06 | 四川科伦博泰生物医药股份有限公司 | 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6058981A (ja) * | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物 |
JPS6025142A (ja) | 1983-07-21 | 1985-02-07 | Matsushita Electric Ind Co Ltd | 表示装置の電極製造方法 |
EP0149884B1 (fr) * | 1983-09-09 | 1992-12-16 | Takeda Chemical Industries, Ltd. | Dérivés de 5-pyridyle-1,3-thiazole, leur préparation et utilisation |
GB9201692D0 (en) * | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
WO1998052941A1 (fr) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | DERIVES DE PYRAZOLE COMME INHIBITEURS DE KINASE p38 |
AR037061A1 (es) | 1997-05-22 | 2004-10-20 | Searle & Co | Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos |
WO1999021555A2 (fr) * | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Antagonistes des recepteurs de l'adenosine a¿3? |
DE60001229T2 (de) | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
JP2000302680A (ja) * | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
CA2381215A1 (fr) * | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Inhibiteurs de p38map kinase |
AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
WO2002040468A1 (fr) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Composes |
CA2436739A1 (fr) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Agent de combinaison |
GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
GB0102665D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
GB0102673D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
WO2002066462A1 (fr) | 2001-02-02 | 2002-08-29 | Glaxo Group Limited | Derives pyrazole contre la surexpression du facteur |
JPWO2002062775A1 (ja) * | 2001-02-02 | 2004-06-10 | 山之内製薬株式会社 | 2−アシルアミノチアゾール誘導体又はその塩 |
EP1363904A1 (fr) | 2001-02-02 | 2003-11-26 | Glaxo Group Limited | Pyrazoles utilises comme inhibiteurs du tgf |
GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
WO2002100433A1 (fr) * | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Compositions medicinales |
AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
AU2003260345A1 (en) | 2002-07-31 | 2004-02-23 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
GB0217780D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
-
2003
- 2003-09-08 JP JP2004568900A patent/JP2006502236A/ja not_active Abandoned
- 2003-09-08 EP EP03797428A patent/EP1542685A1/fr not_active Withdrawn
- 2003-09-08 PL PL03375974A patent/PL375974A1/xx not_active Application Discontinuation
- 2003-09-08 BR BR0314577-8A patent/BR0314577A/pt not_active IP Right Cessation
- 2003-09-08 EA EA200500376A patent/EA200500376A1/ru unknown
- 2003-09-08 CA CA002497971A patent/CA2497971A1/fr not_active Abandoned
- 2003-09-08 AU AU2003260810A patent/AU2003260810A1/en not_active Abandoned
- 2003-09-08 AP AP2005003260A patent/AP2005003260A0/xx unknown
- 2003-09-08 MX MXPA05002982A patent/MXPA05002982A/es unknown
- 2003-09-08 OA OA1200500076A patent/OA12927A/en unknown
- 2003-09-08 KR KR1020057004575A patent/KR20050057393A/ko not_active Application Discontinuation
- 2003-09-08 CN CNA038221594A patent/CN1681502A/zh active Pending
- 2003-09-08 WO PCT/IB2003/003825 patent/WO2004026307A1/fr active Application Filing
- 2003-09-16 AR ARP030103360A patent/AR041276A1/es unknown
- 2003-09-16 UY UY27981A patent/UY27981A1/es not_active Application Discontinuation
- 2003-09-16 PE PE2003000947A patent/PE20050074A1/es not_active Application Discontinuation
- 2003-09-17 TW TW092125634A patent/TW200412346A/zh unknown
- 2003-09-17 US US10/667,183 patent/US7053095B2/en not_active Expired - Fee Related
- 2003-09-17 PA PA20038583401A patent/PA8583401A1/es unknown
-
2005
- 2005-02-24 NO NO20051010A patent/NO20051010L/no unknown
- 2005-02-24 IS IS7713A patent/IS7713A/is unknown
- 2005-03-16 CO CO05024528A patent/CO5540390A2/es not_active Application Discontinuation
- 2005-03-17 EC EC2005005681A patent/ECSP055681A/es unknown
- 2005-03-17 HR HR20050251A patent/HRP20050251A2/hr not_active Application Discontinuation
- 2005-03-18 MA MA28156A patent/MA27442A1/fr unknown
-
2006
- 2006-02-07 US US11/349,481 patent/US20060128761A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AP2005003260A0 (en) | 2005-03-31 |
US20040110798A1 (en) | 2004-06-10 |
CO5540390A2 (es) | 2005-07-29 |
UY27981A1 (es) | 2004-04-30 |
PE20050074A1 (es) | 2005-03-21 |
IS7713A (is) | 2005-02-24 |
MXPA05002982A (es) | 2005-06-22 |
PA8583401A1 (es) | 2004-04-23 |
ECSP055681A (es) | 2005-05-30 |
WO2004026307A1 (fr) | 2004-04-01 |
KR20050057393A (ko) | 2005-06-16 |
CA2497971A1 (fr) | 2004-04-01 |
PL375974A1 (en) | 2005-12-12 |
EP1542685A1 (fr) | 2005-06-22 |
NO20051010L (no) | 2005-05-31 |
JP2006502236A (ja) | 2006-01-19 |
CN1681502A (zh) | 2005-10-12 |
HRP20050251A2 (en) | 2005-10-31 |
AR041276A1 (es) | 2005-05-11 |
US20060128761A1 (en) | 2006-06-15 |
OA12927A (en) | 2006-10-13 |
EA200500376A1 (ru) | 2005-08-25 |
TW200412346A (en) | 2004-07-16 |
BR0314577A (pt) | 2005-08-09 |
US7053095B2 (en) | 2006-05-30 |
AU2003260810A1 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27442A1 (fr) | Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
MA27441A1 (fr) | Composes d'imidazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
MA27440A1 (fr) | Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf) | |
MA27443A1 (fr) | Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
MA27444A1 (fr) | Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
MA27451A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
NZ542622A (en) | Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol | |
MA26861A1 (fr) | Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires | |
ATE402929T1 (de) | Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf) | |
MA27661A1 (fr) | Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant | |
MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
MA26946A1 (fr) | Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases. | |
MXPA05008148A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf). | |
MA27156A1 (fr) | NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI | |
MA27095A1 (fr) | Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer | |
MA27840A1 (fr) | Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2 | |
MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
AP1408A (en) | Phenyl yanthine derivatives. | |
EP0065513A1 (fr) | Compositions pharmaceutiques antimycotiques synergiques et leur procede de preparation. | |
MA26690A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
MA27676A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
NZ304291A (en) | Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof | |
FR2716883B1 (fr) | Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant. |